Disease Markers

Research Article

Beta-3-adrenergic Receptor rs4994 Polymorphism Is a Potential Biomarker for the Development of Nonalcoholic Fatty Liver Disease in Overweight/Obese Individuals

Table 8

The association between the ADRB3 rs4994 genotype and the risk of NAFLD in normal-weight and overweight/obese subjects, as determined using 5,000 randomly sampled data sets.


Weight status	ADRB3 genotype	NAFLD		OR [95% CI]	value^†
Weight status	ADRB3 genotype	Absent	Present	OR [95% CI]	value^†

Normal-weight	T/T	1357 (82.3)	292 (17.7)	1
	T/C	687 (76.5)	211 (23.5)	1.38 [1.12–1.70]	<0.01
	C/C	88 (80.7)	21 (19.3)	1.38 [0.82–2.32]	0.22

Overweight/obese	T/T	1169 (81.5)	266 (18.5)	1
	T/C	635 (78.6)	173 (21.4)	1.16 [0.93–1.46]	0.183
	C/C	62 (61.4)	39 (38.6)	3.26 [2.08–5.12]	<0.001

Overweight	T/T	990 (81.2)	229 (18.8)	1
	T/C	538 (78.7)	146 (21.3)	1.14 [0.89–1.45]	0.30
	C/C	52 (59.8)	35 (40.2)	3.76 [2.31–6.13]	<0.01

ADRB3: beta-3-adrenergic receptor; NAFLD: nonalcoholic fatty liver disease; BMI: body mass index; OR: odds ratio; CI: confidence interval; NAFLD: nonalcoholic fatty liver disease. Data are the number (%). Adjusted by age, BMI, diabetes, and dyslipidemia. ^†Analyzed using a logistic regression analysis.